摘要
目的系统性评价前列地尔联合生长抑素治疗重症急性胰腺炎的疗效和安全性。方法检索PubMed、Cochrane library、Web of Science、万方数据库、中国知网数据库、中国生物医学数据库,检索时限均设定为各数据库建库至2015年11月,收集所有前列地尔联合生长抑素治疗重症急性胰腺炎的随机对照试验,应用RevMan 5.3软件对数据进行Meta分析。结果纳入11篇文献,共927例患者。Meta分析结果显示:与对照组相比,前列地尔联合生长抑素治疗组可以显著提高总有效率[OR=5.45,95%CI(3.48,8.52),P<0.01],改善临床症状缓解时间[均数差(MD)=-15.20,95%CI(-18.17,-12.23),P<0.01],血淀粉酶[MD=-26.59,95%CI(-29.85,-23.34),P<0.01],血C反应蛋白[MD=-23.95,95%CI(-27.68,-20.22),P<0.01],血白细胞介素-6[MD=-12.40,95%CI(-15.69,-9.11),P<0.01],组间比较差异均有统计学意义。此外,不良反应发生率较低。结论在传统治疗基础上加用前列地尔联合生长抑素可以有效提高重症急性胰腺炎的治疗效果,且安全性高,值得临床推广。
Objective To systematically estimate the efficacy and safety of alprostadil combined with somatostatin in the treatment of severe acute pancreatitis.Methods The database of PubMed,Cochrane library,Web of Science,Wanfang,CBM and CNKI were searched to collect all the random controlled trials（RCT）on alprostadil combined with somatostatin in the treatment of severe acute pancreatitis,the retrieval time was from each database establishment to December 2015,and Meta-analysis was performed by using RevMan 5.3software.Results A total of 11 articles involving 927 patients were included.The meta-analysis results showed：compared with the control group,alprostadil combined with somatostatin could significantly improve the total effective rate[OR=5.45,95%CI（3.48,8.52）,P〈0.01],shortened the relief time of clinical symptoms[MD=-15.20,95%CI（-18.17,-12.23）,P〈0.01],promoted serum amylase recovery[MD=-26.59,95%CI（-29.85,-23.34）,P〈0.01],promoted CRP recovery[MD=-23.95,95%CI（-27.68,-20.22）,P〈0.01],promoted IL-6recovery[MD=-12.40,95%CI（-15.69,-9.11）,P〈0.01],the difference between the two groups was statistically significant.Additionally,the adverse reactions incidence was low.Conclusion Alprostadil combined with somatostatin could promote the therapeutic efficacy and safety in the patients with severe acute pancreatitis,which is worthy of clinical promotion.
出处
《重庆医学》
CAS
北大核心
2017年第2期211-214,共4页
Chongqing medicine
